iASPP Inhibition: Increased Options in Targeting the p53 Family for Cancer Therapy
Authors:
Open Access
- 1 July 2008
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 68 (13) , 4959-4962
Abstract
Strategies to induce p53 for cancer therapy offer appeal but many tumors harbor inactivating p53 mutations. One way to address this situation may be to activate the p53-related protein p73, which functions similarly, but unlike p53, is rarely lost or mutated in cancer. Along these lines, a recent study reports that a p53-derived peptide that targets iASPP—a common negative regulator of p53 family members—can effectively trigger tumor cell death by a p73-dependent mechanism. These findings promote further study of iASPP targeting as a therapeutic strategy to activate p73. [Cancer Res 2008;68(13):4959–62]Keywords
This publication has 20 references indexed in Scilit:
- Expression of the RAI gene is conducive to apoptosis: Studies of induction and interferenceExperimental Cell Research, 2007
- A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivoJournal of Clinical Investigation, 2007
- p53 in health and diseaseNature Reviews Molecular Cell Biology, 2007
- Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenograftsProceedings of the National Academy of Sciences, 2006
- Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2Molecular Cancer Therapeutics, 2006
- Splicing DNA-damage responses to tumour cell deathBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2004
- Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compoundNature Medicine, 2002
- Pharmacological Rescue of Mutant p53 Conformation and FunctionScience, 1999
- Regulation of p53 stability by Mdm2Nature, 1997
- Mdm2 promotes the rapid degradation of p53Nature, 1997